[ad_1]
Researchers from the US have found a weak point in several coronaviruses, including COVID-19, SARS-CoV-2.
The authors of the present study from the Institute of Biomedical Sciences at the University of Georgia point out that the coronaviruses SARS-CoV-1, SARS-CoV-2 and MERS-CoV may have similar “weaknesses”, allowing the development of a drug capable of to beat them. .
The researchers identified around 300 proteins that are produced in the body after infection and interact with the SARS-CoV-2 coronavirus. In particular, a protein called Tom70 caught their attention.
The receptor protein in question is a mitochondrial enzyme that binds to the Orf9b coronavirus genome and helps viruses take over the body. According to scientists, it is a suitable “target” for drugs with a wide spectrum of action.
Modern antiviral drugs target viral enzymes, but they often mutate and develop resistance to the drug. Scientists have concluded that protein exposure is a more effective method of treating patients.
Reuters, meanwhile, said that according to an Oxford University study, which looked at 58 people and looked at the long-term effects of COVID-19, more than half of the patients with the disease were discharged from the hospital. they still showed symptoms: shortness of breath, fatigue, anxiety, depression, two to three months after the initial infection.
